3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Vascular Diseases
1
Paraproteinemias
1
Neoplasms, Plasma Cell
1
Neoplasms by Histologic Type
1
Neoplasms
1
Multiple Myeloma
1
Lymphoproliferative Disorders
1
Lymphoma
1
Lymphatic Diseases
1
Immunoproliferative Disorders
1
Hemorrhagic Disorders
1
Hematologic Diseases
1
Cardiovascular Diseases
1
Blood Protein Disorders
1
Interventions
Bortezomib
4
fludarabine
3
Lenalidomide
3
dacetuzumab
2
Tacrolimus
2
Dexamethasone
2
Alemtuzumab
2
plerixafor
1
ofatumumab
1
isatuximab
1
fludarabine phosphate
1
ficlatuzumab
1
epratuzumab
1
Whole-Body Irradiation
1
Vorinostat
1
Stem Cell Transplantation
1
Rifaximin
1
Mycophenolic Acid
1
KW-2478
1
Hsp90 inhibitor KU757
1
Granulocyte Colony-Stimulating Factor
1
Erlotinib Hydrochloride
1
Cyclophosphamide
1
Clonal Hematopoiesis
1
Chromatin Immunoprecipitation Sequencing
1
Calcium Dobesilate
1
CLR1404
1
Busulfan
1
Blood Cell Count
1
ARQ531
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Paraproteinemias
×
ficlatuzumab
×
Lymphoid
×
Clear all
NCT00725634
2014-01-27
P05538
AVEO Pharmaceuticals, Inc.
Phase 1
Completed
41 enrolled